F
REGN icon

F3Logic’s Regeneron Pharmaceuticals REGN Stock Holding History

F3Logic’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-435
Closed -$244 – 371
2020
Q3 		$244 Sell
435
-64
-13% -$38.8K 0.01% 426
2020
Q2 		$315K Buy
+499
New +$283K 0.06% 132
2019
Q3 		– Sell
-8,895
Closed -$2.79M – 201
2019
Q2 		$2.79M Sell
8,895
-109
-1% -$36.3K 0.52% 41
2019
Q1 		$3.7M Buy
+9,004
New +$3.71M 0.8% 22

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

F3Logic's REGN Position: Q4 2020 in Review

F3Logic sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 435 shares — an estimated $244 sold.

F3Logic first reported a position in REGN in Q1 2019 and held it in 4 quarters. The position peaked at $3.7M in Q1 2019. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • F3Logic reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • F3Logic sold 435 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $244.
  • F3Logic first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • F3Logic's Regeneron Pharmaceuticals position peaked at $3.7M in Q1 2019.
  • 903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on F3Logic's 13F filing for Q4 2020, filed 12 Feb 2021.